Prostate Cancer – Drug Pipeline Analysis and Market Forecasts to 2015
01/06/2010

Prostate Cancer Market is Forecast to Show High Growth till 2015

Online PR News – 06-January-2010 – – GlobalData estimates that the global prostate cancer market was valued at $5.4 billion in 2009 and is forecast to grow at a compound annual growth rate (CAGR) of 6% to reach $7.8 billion by 2015. This high growth forecast is mainly due to the strong pipeline landscape with innovative first in class drugs and also due to high population growth. Prospective market entrants will face significant challenges, including; low treatment seeking rate, low diagnosis rate, low prescription rates and the availability of generics with better efficacy and safety profiles.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Prostate-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

GlobalData’s research indicates that the prevailing pipeline landscape is weak with few players and none of their products seem to be satisfying the unmet needs of the prostate cancer market. The current market provides considerable scope for pipeline drugs that are strong in terms of efficacy and safety. As patients, especially in the developed economies, continue to be aware of the latest technological developments; increased efficacy, tolerability and safety profiles will be the key factors driving the acceptance and market penetration of new products. Due to the deficiencies of existing the market continues to offer opportunities for stronger pipeline candidates. The existing market leaders will face significant challenges in maintaining their market shares as many of the current pipeline products are first-in-class with proven superiority in offering therapeutic performance.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Prostate-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

GlobalData predicts that Sanofi-aventis, Pfizer Inc., AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline plc will become the leading competitors in the global prostate cancer market. The current competitive landscape comprises seven major products, none of which have a dominant position. The current emphasis has been on treating the symptoms of the disease without providing an absolute cure. The above named five companies, with some of the most technologically advanced products in their pipeline portfolio, are expected to attract the most investor attention in the coming years. Any company that successfully targets disease modification will become a major player in the prostate cancer market.

GlobalData, the industry analysis specialist’s new report, “Prostate Cancer – Drug Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global prostate cancer market. The report identifies the key trends shaping and driving the dynamism in the global prostate cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global prostate cancer market.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Prostate-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

Or visit our report store: http://www.globaldata.com/reportsotre